Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses

Martin Hoyle; Toby Pavey; Oriana Ciani; Louise Crathorne; Tracey Jones-Hughes; Chris Cooper; Leeza Osipenko; Meena Venkatachalam; Claudius Rudin; Obi Ukoumunne; Ruth Garside; Rob Anderson

Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses

Martin Hoyle, Toby Pavey, Oriana Ciani, Louise Crathorne, Tracey Jones-Hughes , Chris Cooper, Leeza Osipenko, Meena Venkatachalam, Claudius Rudin, Obi Ukoumunne, Ruth Garside, Rob Anderson

Research output: Book/Report › Commissioned report

Original language	English
Publisher	University of Exeter
Commissioning body	National Institute for Health and Care Excellence (NICE)
Number of pages	242
Publication status	Published - 2011
Externally published	Yes

Access to Document

https://www.nice.org.uk/guidance/ta426/documents/committee-papers-2

Cite this

Hoyle, M., Pavey, T., Ciani, O., Crathorne, L., Jones-Hughes , T., Cooper, C., Osipenko, L., Venkatachalam, M., Rudin, C., Ukoumunne, O., Garside, R., & Anderson, R. (2011). Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. University of Exeter. https://www.nice.org.uk/guidance/ta426/documents/committee-papers-2

@book{b631922096c54781992ed545a38b53cf,

title = "Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses",

author = "Martin Hoyle and Toby Pavey and Oriana Ciani and Louise Crathorne and Tracey Jones-Hughes and Chris Cooper and Leeza Osipenko and Meena Venkatachalam and Claudius Rudin and Obi Ukoumunne and Ruth Garside and Rob Anderson",

year = "2011",

language = "English",

publisher = "University of Exeter",

}

Hoyle, M, Pavey, T, Ciani, O, Crathorne, L, Jones-Hughes , T, Cooper, C, Osipenko, L, Venkatachalam, M, Rudin, C, Ukoumunne, O, Garside, R & Anderson, R 2011, Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. University of Exeter. <https://www.nice.org.uk/guidance/ta426/documents/committee-papers-2>

TY - BOOK

T1 - Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia

T2 - systematic reviews and economic analyses

AU - Hoyle, Martin

AU - Pavey, Toby

AU - Ciani, Oriana

AU - Crathorne, Louise

AU - Jones-Hughes , Tracey

AU - Cooper, Chris

AU - Osipenko, Leeza

AU - Venkatachalam, Meena

AU - Rudin, Claudius

AU - Ukoumunne, Obi

AU - Garside, Ruth

AU - Anderson, Rob

PY - 2011

Y1 - 2011

UR - https://www.nice.org.uk/guidance/ta426/evidence

M3 - Commissioned report

BT - Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia

PB - University of Exeter

ER -

Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses

Access to Document

Other files and links

Cite this